| Autor: |
C. Gerard, B. Shum, P. Nathan, S. Turajlic |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Immuno-Oncology and Technology, Vol 19, Iss , Pp 100386- (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2590-0188 |
| DOI: |
10.1016/j.iotech.2023.100386 |
| Popis: |
Uveal melanoma (UM) is the most common ocular malignancy in adults, associated with the poorest prognosis, with metastatic disease occurring in up to 50% of patients. In contrast to metastatic cutaneous melanoma, the use of immune checkpoint inhibitors is associated with poor outcomes in metastatic uveal melanoma (mUM). Tebentafusp, a bispecific molecule, has recently become the first treatment in decades to improve overall survival for mUM. This review summarises the existing and emerging immuno-oncology approaches for the treatment of mUM, and biomarkers of response and resistance to the same. Finally, we propose future research directions that could maximise treatment benefit to a wider pool of patients with UM. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
